~~<i id='D3550D804E'><strike id='D3550D804E'><tt id='D3550D804E'><pre id='D3550D804E'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

focus

author：comprehensive 2025-10-02 21:04:49 - browse：56727

Eli Lilly said Friday that it will acquire Dermira, a small biotech developing drugs for chronic skin conditions, for $1.1 billion.

The centerpiece of the deal is the Dermira drug called lebrikizumab that aims to treat people suffering from moderate-to-severe atopic dermatitis, the most common form of eczema, a disease characterized by inflamed, itchy, and scaly skin.

Phase 3 clinical trials of lebrikizumab in atopic dermatitis are underway. If successful, the drug could compete against Dupixent, which has grown into a commercial blockbuster for Regeneron Pharmaceuticals and Sanofi.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Sports medicine is finally prioritizing gender equality
Next article： How to fix the rural physician shortage in the U.S.

hotspot

Wikipedia

explore

hotspot

Wikipedia

leisure time

CAPTIONCORRECTION:CORRECTSDATE:FILE-AchairremainsuprightintheareaofamassshootingincidentintheSouther

WSS

Kale crackers and hibiscus tea: My five days on a 'fasting diet'

Clinical trials giant ICON acquires HumanFirst

Baltimore teen accused of firing into crowd during block party mass shooting

ActiGraph execs on goal of drug approvals with digital endpoints

Cancer drug shortages' outsize impact on ovarian cancer patients

Kenai launches with $82 million for Parkinson’s stem cell therapy

focus

focus

hotspot

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

Liz Cheney makes 1st public comment since Trump's election interference indictments

George Santos makes 1st court appearance after pleading not guilty to 13 counts

Congress gives doctors Medicare pay bump

Medical records are filled with copy

Special counsel raises new conflict of interest concerns for De Oliveira's lawyer

New air purifier tech could be key to improving indoor air quality

Clinical trials must include more disabled people

Medical leaders decry Supreme Court decision on affirmative action

ActiGraph execs on goal of drug approvals with digital endpoints

Wikipedia

Hilary expected to bring catastrophic, life

Change Healthcare cyberattack outage could last weeks

Majority of Americans think Trump's Ga. election interference case is serious: POLL

Scientists unlock the key to scar

FDA does about

ProMED sees offers of support, but its future remains unclear

explore

hotspot

Wikipedia

leisure time